Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Cancer Survivors Found to Be at Greater Risk of Frailty-Related Bone Fractures

November 18, 2022
By Nicholas Wrigley
Article

Factors such as chemotherapy treatment and a cancer diagnosis within the past 5 years were associated with a greater risk of frailty-related bone fractures among older cancer survivors, according to findings from a recent cohort study.

Cancer survivors have a significantly higher risk of frailty-related bone fractures for several years after diagnosis vs those without a history of cancer, according to findings from a recent study published in JAMA Oncology.

Older adults with a history of cancer were found to have a 57% greater risk of fractures in the first year after diagnosis (HR 1.57; 95% CI, 1.38-1.79) vs those without. The risk was especially elevated for those diagnosed with distant metastases 1 to 4 years prior to the study (HR 2.12; 95% CI, 1.75-2.58). This disparity in risk derived largely from vertebral (HR 2.46; 95% CI, 1.93-3.13) and pelvic (HR, 2.46; 95% CI 1.84-3.29) fractures. The risk of radial fracture meanwhile did not substantially vary based on history of cancer (HR 1.09; 95% CI, 0.64-1.87).

“Cancer survivors are at higher risk of bone fractures likely because of higher rates of osteoporosis coupled with low muscle mass, poor balance, and unexpected changes in gait,” the investigators wrote. “One novel finding in this study was the difference in risk by fracture site….[It] is important to understand the differences in risk by fracture site because each fracture type is associated with certain health care costs and risks of subsequent morbidity and mortality. Pelvic fractures, in particular, are highly associated with further health issues, including mortality, and account for nearly 77% of all costs incurred from incident fractures.”

Other relevant risk factors included treatment modality, lifestyle, and sex. Survivors of cancer who received chemotherapy were 31% more likely to have a fracture vs those who didn’t receive chemotherapy (HR 1.31; 95% CI, 1.09-1.57) in the first 4 years after diagnosis and 22% more likely 5 or more years beyond diagnosis (HR 1.22; 95% CI, 0.99-1.51). Additionally, survivors who were current smokers at the time of the study were more than twice as likely to have fractures (HR 2.27; 95% CI, 1.55-3.33) as those who never smoked. The risk of fracture was lower among physically active survivors 5 or more years after diagnosis (HR 0.76; 95% CI, 0.54-1.07), but this correlation was not statistically significant. Higher BMI (≥25) was also associated with lower risk of fracture for those with (HR 0.72; 95% CI, 0.62-0.85) and without (HR 0.78; 95% CI, 0.75-0.81) a history of cancer. Men were generally less likely to experience fractures than women, including in those without a history of cancer (HR 0.51; 95% CI, 0.48-0.54), in survivors 1 to 4 years after diagnosis (HR 0.53; 95% CI, 0.41-0.69), and in survivors 5 or more years beyond (HR, 0.74; 95% CI, 0.54-1.01), though the latter correlation was not statistically significant.

This longitudinal cohort study examined 92,413 eligible participants out of 116,355 adults who completed the 1999 Cancer Prevention Study II Nutrition Cohort survey and were linked with Medicare claims from 1999 to 2017. The vast majority of this study population were White (97.9%) and older than 60 years (95.8%) at the time of the survey. The median age was 69.4 years, and most participants were women (56%). Most either met (24.1%) or significantly exceeded (32.3%) the guidelines for moderate to vigorous physical activity, and most (54.2%) had a BMI of 25 or greater. Current smokers comprised 4.7% of the population, with former smokers comprising a further 48.6%.

Incident fractures affected 12,943 participants in total. The primary analysis only included first fractures because roughly 4% (n = 3793) of participants experienced more than one; further exploratory analyses assessed the risks related to multiple fractures.

“Future studies are needed that explore the associations of [moderate- to vigorous-intensity physical activity], strength training, smoking, alcohol use, or diet quality across the life course, both before and after diagnosis, with fracture risk in [survivors of cancer],” the investigators concluded, writing nonetheless that “[these] survivors, especially those who received chemotherapy or received a cancer diagnosis more recently (<5 years), may benefit from clinical guidance on frailty-related fracture prevention.”

Reference

Rees-Punia E, Newton CC, Parsons HM, et al. Fracture risk among older cancer survivors compared with older adults without a history of cancer. JAMA Oncol. Published online November 3, 2022. doi:10.1001/jamaoncol.2022.5153

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
The pediatric care wing of the Jack & Sheryl Morris Cancer Center is intended to accommodate the physical and emotional needs of younger patients with cancer.
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Leadership of a new cancer center as part of JFK University Medical Center discuss how they can support frontline clinicians.
Related Content
Advertisement

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

Olanzapine May Prevent Radiation-Induced Nausea and Vomiting

Roman Fabbricatore
June 3rd 2025
Article

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.


Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.


Experts highlight research at the 2025 ASCO Annual Meeting that may move the needle in gynecologic cancers, hematologic malignancies, and other fields.

ASCO 2025: Key Anticipated Updates Across Cancer Care

Russ Conroy
May 28th 2025
Article

Experts highlight research at the 2025 ASCO Annual Meeting that may move the needle in gynecologic cancers, hematologic malignancies, and other fields.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


CHMP Recommends Mirdametinib for EU Approval in Adult/Pediatric NF1-PN

CHMP Recommends Mirdametinib for EU Approval in Adult/Pediatric NF1-PN

Tim Cortese
May 23rd 2025
Article

The EMA’s CHMP has adopted a positive opinion for mirdametinib in patients with inoperable plexiform neurofibromas of neurofibromatosis type 1.


GLP-1 Use Not Linked to Increased Obesity-Related Cancer Rates

GLP-1 Use Not Linked to Increased Obesity-Related Cancer Rates

Ariana Pelosci
May 22nd 2025
Article

There was a 7% lower incidence of obesity-related cancer with GLP-1 receptor agonist use.

Related Content
Advertisement

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

Olanzapine May Prevent Radiation-Induced Nausea and Vomiting

Roman Fabbricatore
June 3rd 2025
Article

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.


Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.


Experts highlight research at the 2025 ASCO Annual Meeting that may move the needle in gynecologic cancers, hematologic malignancies, and other fields.

ASCO 2025: Key Anticipated Updates Across Cancer Care

Russ Conroy
May 28th 2025
Article

Experts highlight research at the 2025 ASCO Annual Meeting that may move the needle in gynecologic cancers, hematologic malignancies, and other fields.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


CHMP Recommends Mirdametinib for EU Approval in Adult/Pediatric NF1-PN

CHMP Recommends Mirdametinib for EU Approval in Adult/Pediatric NF1-PN

Tim Cortese
May 23rd 2025
Article

The EMA’s CHMP has adopted a positive opinion for mirdametinib in patients with inoperable plexiform neurofibromas of neurofibromatosis type 1.


GLP-1 Use Not Linked to Increased Obesity-Related Cancer Rates

GLP-1 Use Not Linked to Increased Obesity-Related Cancer Rates

Ariana Pelosci
May 22nd 2025
Article

There was a 7% lower incidence of obesity-related cancer with GLP-1 receptor agonist use.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.